Hypermethylation of Mismatch Repair Gene HMSH2 Associates with Platinum-resistant Disease in Epithelial Ovarian Cancer

Overview

Journal Clin Epigenetics

Publisher Biomed Central

Specialty Genetics

Date 2019 Nov 1

PMID 31666131

Citations 15

Authors

Hua Tian

Li Yan

Li Xiao-Fei

Sun Hai-Yan

Chen Juan

Kang Shan

Affiliations

Soon will be listed here.

Abstract

Purpose: One major reason of the high mortality of epithelial ovarian cancer (EOC) is due to platinum-based chemotherapy resistance. Aberrant DNA methylation may be a potential mechanism underlying the development of platinum resistance in EOC. The purpose of this study is to discover potential aberrant DNA methylation that contributes to drug resistance.

Methods: By initially screening of 16 platinum-sensitive/resistant samples from EOC patients with reduced representation bisulfite sequencing (RRBS), the upstream region of the hMSH2 gene was discovered hypermethylated in the platinum-resistant group. The effect of hMSH2 methylation on the cellular response to cisplatin was explored by demethylation and knockdown assays in ovarian cancer cell line A2780. Matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry was employed to examine the methylation levels of hMSH2 upstream region in additional 40 EOC patient samples. RT-qPCR and IHC assay was used to detect the hMSH2 mRNA and protein expression in extended 150 patients.

Results: RRBS assay discovered an upstream region from - 1193 to - 1125 of hMSH2 was significant hypermethylated in resistant EOC patients (P = 1.06 × 10). In vitro analysis demonstrated that global demethylation increased cisplatin sensitivity along with a higher expression of the hMSH2 mRNA and protein. Knockdown hMSH2 reduced the cell sensitivity to cisplatin. MALDI-TOF mass spectrometry assay validated the strong association of hypermethylation of hMSH2 upstream region with platinum resistance. Spearman's correlation analysis revealed a significantly negative connection between methylation level of hMSH2 upstream region and its expression. The Kaplan-Meier analyses showed the high methylation of hMSH2 promoter region, and its low expressions are associated with worse survival. In multivariable models, hMSH2 low expression was an independent factor predicting poor outcome (P = 0.03, HR = 1.91, 95%CI = 1.85-2.31).

Conclusion: The hypermethylation of hMSH2 upstream region is associated with platinum resistant in EOC, and low expression of hMSH2 may be an index for the poor prognosis.

Citing Articles

Molecular mechanisms of cisplatin resistance in ovarian cancer.

Jiang C, Shen C, Ni M, Huang L, Hu H, Dai Q Genes Dis. 2024; 11(6):101063.

PMID: 39224110 PMC: 11367050. DOI: 10.1016/j.gendis.2023.06.032.

Novel players in the development of chemoresistance in ovarian cancer: ovarian cancer stem cells, non-coding RNA and nuclear receptors.

Alam S, Giri P Cancer Drug Resist. 2024; 7:6.

PMID: 38434767 PMC: 10905178. DOI: 10.20517/cdr.2023.152.

Peroxiredoxin-1 as a molecular chaperone that regulates glutathione S-transferase P1 activity and drives mutidrug resistance in ovarian cancer cells.

Fan C, Yuan S, Zhang Y, Nie Y, Xiang L, Luo T Biochem Biophys Rep. 2024; 37:101639.

PMID: 38288281 PMC: 10823101. DOI: 10.1016/j.bbrep.2024.101639.

MiR-590-5p promotes cisplatin resistance via targeting hMSH2 in ovarian cancer.

Li B, Xu X, Zheng L, Jiang X, Lin J, Zhang G Mol Biol Rep. 2023; 50(8):6819-6827.

PMID: 37392283 DOI: 10.1007/s11033-023-08599-8.

The role of DNA methylation in ovarian cancer chemoresistance: A narrative review.

Song K, Artibani M Health Sci Rep. 2023; 6(5):e1235.

PMID: 37123549 PMC: 10140645. DOI: 10.1002/hsr2.1235.

References

Duckett D, Drummond J, Murchie A, Reardon J, Sancar A, Lilley D . Human MutSalpha recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct. Proc Natl Acad Sci U S A. 1996; 93(13):6443-7. PMC: 39042. DOI: 10.1073/pnas.93.13.6443. View

Bauerschlag D, Ammerpohl O, Brautigam K, Schem C, Lin Q, Weigel M . Progression-free survival in ovarian cancer is reflected in epigenetic DNA methylation profiles. Oncology. 2011; 80(1-2):12-20. DOI: 10.1159/000327746. View

Yan B, Yin F, Wang Q, Zhang W, Li L . Integration and bioinformatics analysis of DNA-methylated genes associated with drug resistance in ovarian cancer. Oncol Lett. 2016; 12(1):157-166. PMC: 4906569. DOI: 10.3892/ol.2016.4608. View

Goodspeed A, Jean A, Costello J . A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer. Eur Urol. 2018; 75(2):242-250. PMC: 6339584. DOI: 10.1016/j.eururo.2018.10.040. View

Song Y, Zuo Y, Qian X, Chen Z, Wang S, Song L . Inhibition of MicroRNA-21-5p Promotes the Radiation Sensitivity of Non-Small Cell Lung Cancer Through HMSH2. Cell Physiol Biochem. 2017; 43(3):1258-1272. DOI: 10.1159/000481839. View

Pignata S, Cecere S, Bois A, Harter P, Heitz F . Treatment of recurrent ovarian cancer. Ann Oncol. 2017; 28(suppl_8):viii51-viii56. DOI: 10.1093/annonc/mdx441. View

Breitling L, Yang R, Korn B, Burwinkel B, Brenner H . Tobacco-smoking-related differential DNA methylation: 27K discovery and replication. Am J Hum Genet. 2011; 88(4):450-7. PMC: 3071918. DOI: 10.1016/j.ajhg.2011.03.003. View

Magnowska M, Surowiak P, Nowak-Markwitz E, Michalak M, Magnowski P, Rokita W . Analysis of hMLH1 and hMSH2 expression in cisplatin-treated ovarian cancer patients. Ginekol Pol. 2009; 79(12):826-34. View

Ponnusamy L, Mahalingaiah P, Chang Y, Singh K . Reversal of epigenetic aberrations associated with the acquisition of doxorubicin resistance restores drug sensitivity in breast cancer cells. Eur J Pharm Sci. 2018; 123:56-69. DOI: 10.1016/j.ejps.2018.07.028. View

10.

Armstrong D . Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist. 2002; 7 Suppl 5:20-8. DOI: 10.1634/theoncologist.7-suppl_5-20. View

11.

Sameer A, Nissar S, Fatima K . Mismatch repair pathway: molecules, functions, and role in colorectal carcinogenesis. Eur J Cancer Prev. 2014; 23(4):246-57. DOI: 10.1097/CEJ.0000000000000019. View

12.

Rocha C, Silva M, Quinet A, Cabral-Neto J, Menck C . DNA repair pathways and cisplatin resistance: an intimate relationship. Clinics (Sao Paulo). 2018; 73(suppl 1):e478s. PMC: 6113849. DOI: 10.6061/clinics/2018/e478s. View

13.

Mello J, Acharya S, Fishel R, Essigmann J . The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Chem Biol. 1996; 3(7):579-89. DOI: 10.1016/s1074-5521(96)90149-0. View

14.

De Leon M, Cardenas H, Vieth E, Emerson R, Segar M, Liu Y . Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer. Gynecol Oncol. 2016; 142(3):539-47. PMC: 4993677. DOI: 10.1016/j.ygyno.2016.06.017. View

15.

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

16.

Pabla N, Ma Z, McIlhatton M, Fishel R, Dong Z . hMSH2 recruits ATR to DNA damage sites for activation during DNA damage-induced apoptosis. J Biol Chem. 2011; 286(12):10411-8. PMC: 3060494. DOI: 10.1074/jbc.M110.210989. View

17.

Seeber L, van Diest P . Epigenetics in ovarian cancer. Methods Mol Biol. 2012; 863:253-69. DOI: 10.1007/978-1-61779-612-8_15. View

18.

Matei D, Ghamande S, Roman L, Secord A, Nemunaitis J, Markham M . A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses. Clin Cancer Res. 2018; 24(10):2285-2293. PMC: 5955794. DOI: 10.1158/1078-0432.CCR-17-3055. View

19.

Borley J, Brown R . Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer. Ann Med. 2015; 47(5):359-69. DOI: 10.3109/07853890.2015.1043140. View

20.

Wang Y, Lu Y, Tseng R, Lin R, Chang J, Chen J . Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples. J Clin Invest. 2003; 111(6):887-95. PMC: 153761. DOI: 10.1172/JCI15475. View